Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Mid- to late-life migraine diagnoses and risk of dementia: a national register-based follow-up study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies

    Research output: Contribution to journalLetterResearchpeer-review

  3. Correction to: Hospital-based headache care during the Covid-19 pandemic in Denmark and Norway

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Hospital-based headache care during the Covid-19 pandemic in Denmark and Norway

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. ICHD-3 is significantly more specific than ICHD-3 beta for diagnosis of migraine with aura and with typical aura

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Calcitonin gene-related peptide (CGRP) has recently been implicated in the pathogenesis of post-traumatic headache (PTH), which raises the prospect for therapeutic use of monoclonal antibodies targeting CGRP or its receptor. Therefore, we decided to assess the efficacy, tolerability, and safety of erenumab for prevention of persistent PTH attributed to mild traumatic brain injury.

METHODS: A single-center, non-randomized, single-arm, open-label study of erenumab for adults aged 18-65 years with persistent PTH. Patients were assigned to receive 140-mg erenumab monthly by two subcutaneous 1-mL injections, given every 4 weeks for 12 weeks. The primary outcome measure was the mean change in number of monthly headache days of moderate to severe intensity from baseline (4-week pretreatment period) to week 9 through 12. Tolerability and safety endpoints were adverse events (i.e. number and type).

RESULTS: Eighty-nine of 100 patients completed the open-label trial. At baseline, the mean monthly number of headache days of moderate to severe intensity was 15.7. By week 9 through 12, the number was reduced by 2.8 days. The most common adverse events were constipation (n = 30) and injection-site reactions (n = 15). Of 100 patients who received at least one dose of erenumab, two patients discontinued the treatment regimen due to adverse events.

CONCLUSIONS: Among patients with persistent PTH, erenumab resulted in a lower frequency of moderate to severe headache days in this 12-week open-label trial. In addition, erenumab was well-tolerated as discontinuations due to adverse events were low. Placebo-controlled randomized clinical trials are needed to adequately evaluate the efficacy and safety of erenumab in patients with persistent PTH.

TRIAL REGISTRATION: ClinicalTrials.Gov, NCT03974360. Registered on April 17, 2019 - Retrospectively registered.

Original languageEnglish
JournalJournal of Headache and Pain
Volume21
Issue number1
Pages (from-to)62-
ISSN1129-2377
DOIs
Publication statusPublished - 2020

    Research areas

  • Clinical management, Concussion, Head injury, Head trauma, Secondary headache

ID: 60053310